Aurora Spine launches Aurora Biologics

Executive Summary

• Aurora Spine Corp. has launched "Aurora Biologics," a new division dedicated to advancing spinal fusion success through biologic innovation, integrating with its existing mechanical fusion systems.
• The launch includes a comprehensive suite of allograft solutions designed to work synergistically with Aurora's implant technologies to enhance patient outcomes and surgical efficiency.
• Management anticipates a significant financial impact, projecting a greater than 30% increase over prior biologic offerings, which is expected to drive stronger margins and create a new profit engine for the company.

Key Details

• New Division: Establishment of Aurora Biologics, creating synergy across Aurora's spine ecosystem (interspinous, lumbar, and sacroiliac fusion systems).
• Product Portfolio: The launch includes three specific allograft solutions:
  • Turbo Fuse fibre putty: A bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment.
  • Osteo Graft DBM putty: A demineralized cortical bone graft with cohesive, mouldable consistency to support bone formation without synthetic carriers.
  • Osteo Bridge sponge strips: A sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration.
• Product Specifications: All biologics are formulated from 100% allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties. They are fully mouldable and cohesive, designed to fill bony defects or augment fusion sites.
• Strategic Impact: The integration aims to provide a seamless, fully integrated portfolio, optimizing the healing phase alongside mechanical fusion systems.
• Financial Projection: CEO Trent J. Northcutt anticipates more than a 30% increase over prior biologic offerings, driving stronger margins and creating a powerful new profit engine.

Notable Quotes

• "Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio... With the addition of Aurora Biologics, we now enhance the healing phase as well, allowing surgeons to deliver a fully optimized fusion procedure from start to finish." — Mathew Goldstone, Chief Commercial Officer
• "Our new Aurora Biologics platform not only reinforces our commitment to improved clinical outcomes but also serves as a strong growth catalyst... By integrating biologics across our minimally invasive product portfolio, we anticipate more than a 30-per-cent increase over prior biologic offerings --driving stronger margins and creating a powerful new profit engine for Aurora Spine." — Trent J. Northcutt, President and Chief Executive Officer